481 related articles for article (PubMed ID: 34445385)
1. T-Cell Responses in Merkel Cell Carcinoma: Implications for Improved Immune Checkpoint Blockade and Other Therapeutic Options.
Gehrcken L; Sauerer T; Schaft N; Dörrie J
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445385
[TBL] [Abstract][Full Text] [Related]
2. Clinical and molecular characteristics associated with response to therapeutic PD-1/PD-L1 inhibition in advanced Merkel cell carcinoma.
Spassova I; Ugurel S; Kubat L; Zimmer L; Terheyden P; Mohr A; Björn Andtback H; Villabona L; Leiter U; Eigentler T; Loquai C; Hassel JC; Gambichler T; Haferkamp S; Mohr P; Pfoehler C; Heinzerling L; Gutzmer R; Utikal JS; Horny K; Schildhaus HU; Habermann D; Hoffmann D; Schadendorf D; Becker JC
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35074902
[TBL] [Abstract][Full Text] [Related]
3. PD-L1 inhibition with avelumab for metastatic Merkel cell carcinoma.
Gaiser MR; Bongiorno M; Brownell I
Expert Rev Clin Pharmacol; 2018 Apr; 11(4):345-359. PubMed ID: 29478343
[TBL] [Abstract][Full Text] [Related]
4. [Immune checkpoint inhibition in Merkel cell carcinoma].
Terheyden P; Mohr A; Langan EA
Hautarzt; 2019 Sep; 70(9):684-690. PubMed ID: 31468071
[TBL] [Abstract][Full Text] [Related]
5. Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial.
D'Angelo SP; Bhatia S; Brohl AS; Hamid O; Mehnert JM; Terheyden P; Shih KC; Brownell I; Lebbé C; Lewis KD; Linette GP; Milella M; Georges S; Shah P; Ellers-Lenz B; Bajars M; Güzel G; Nghiem PT
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32414862
[TBL] [Abstract][Full Text] [Related]
6. Current and preclinical treatment options for Merkel cell carcinoma.
Celikdemir B; Houben R; Kervarrec T; Samimi M; Schrama D
Expert Opin Biol Ther; 2023; 23(10):1015-1034. PubMed ID: 37691397
[TBL] [Abstract][Full Text] [Related]
7. Current concepts and approaches to merkel cell carcinoma.
Babadzhanov M; Doudican N; Wilken R; Stevenson M; Pavlick A; Carucci J
Arch Dermatol Res; 2021 Apr; 313(3):129-138. PubMed ID: 32666149
[TBL] [Abstract][Full Text] [Related]
8. Predominance of Central Memory T Cells with High T-Cell Receptor Repertoire Diversity is Associated with Response to PD-1/PD-L1 Inhibition in Merkel Cell Carcinoma.
Spassova I; Ugurel S; Terheyden P; Sucker A; Hassel JC; Ritter C; Kubat L; Habermann D; Farahpour F; Saeedghalati M; Peiffer L; Kumar R; Schrama D; Hoffmann D; Schadendorf D; Becker JC
Clin Cancer Res; 2020 May; 26(9):2257-2267. PubMed ID: 31932494
[TBL] [Abstract][Full Text] [Related]
9. Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma.
Nghiem P; Bhatia S; Lipson EJ; Sharfman WH; Kudchadkar RR; Brohl AS; Friedlander PA; Daud A; Kluger HM; Reddy SA; Boulmay BC; Riker A; Burgess MA; Hanks BA; Olencki T; Kendra K; Church C; Akaike T; Ramchurren N; Shinohara MM; Salim B; Taube JM; Jensen E; Kalabis M; Fling SP; Homet Moreno B; Sharon E; Cheever MA; Topalian SL
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33879601
[TBL] [Abstract][Full Text] [Related]
10. Merkel Cell Carcinoma in the Age of Immunotherapy: Facts and Hopes.
Colunga A; Pulliam T; Nghiem P
Clin Cancer Res; 2018 May; 24(9):2035-2043. PubMed ID: 29217527
[TBL] [Abstract][Full Text] [Related]
11. Quality Is King: Fundamental Insights into Tumor Antigenicity from Virus-Associated Merkel Cell Carcinoma.
Lahman MC; Paulson KG; Nghiem PT; Chapuis AG
J Invest Dermatol; 2021 Aug; 141(8):1897-1905. PubMed ID: 33863500
[TBL] [Abstract][Full Text] [Related]
12. Pembrolizumab and other immune checkpoint inhibitors in locally advanced or metastatic Merkel Cell Carcinoma: safety and efficacy.
Marchand A; Kervarrec T; Bhatia S; Samimi M
Expert Rev Anticancer Ther; 2020 Dec; 20(12):1093-1106. PubMed ID: 33044876
[TBL] [Abstract][Full Text] [Related]
13. Polyomavirus-driven Merkel cell carcinoma: Prospects for therapeutic vaccine development.
Tabachnick-Cherny S; Pulliam T; Church C; Koelle DM; Nghiem P
Mol Carcinog; 2020 Jul; 59(7):807-821. PubMed ID: 32219902
[TBL] [Abstract][Full Text] [Related]
14. Modern diagnostics and treatment of Merkel cell carcinoma.
Weilandt J; Peitsch WK
J Dtsch Dermatol Ges; 2023 Dec; 21(12):1524-1546. PubMed ID: 37875785
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy for Merkel Cell Carcinoma.
Nagase K; Narisawa Y
Curr Treat Options Oncol; 2018 Sep; 19(11):57. PubMed ID: 30238195
[TBL] [Abstract][Full Text] [Related]
16. MHC class-I downregulation in PD-1/PD-L1 inhibitor refractory Merkel cell carcinoma and its potential reversal by histone deacetylase inhibition: a case series.
Ugurel S; Spassova I; Wohlfarth J; Drusio C; Cherouny A; Melior A; Sucker A; Zimmer L; Ritter C; Schadendorf D; Becker JC
Cancer Immunol Immunother; 2019 Jun; 68(6):983-990. PubMed ID: 30993371
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of T-cell-mediated immune response via the PD-1/ PD-L1 axis in cholangiocarcinoma cells.
Suriyo T; Fuangthong M; Artpradit C; Ungtrakul T; Sricharunrat T; Taha F; Satayavivad J
Eur J Pharmacol; 2021 Apr; 897():173960. PubMed ID: 33617828
[TBL] [Abstract][Full Text] [Related]
18. Immune Checkpoint Inhibitors and Beyond: An Overview of Immune-Based Therapies in Merkel Cell Carcinoma.
Samimi M
Am J Clin Dermatol; 2019 Jun; 20(3):391-407. PubMed ID: 30784027
[TBL] [Abstract][Full Text] [Related]
19. Response durability after cessation of immune checkpoint inhibitors in patients with metastatic Merkel cell carcinoma: a retrospective multicenter DeCOG study.
Stege HM; Haist M; Schultheis S; Fleischer MI; Mohr P; Ugurel S; Terheyden P; Thiem A; Kiecker F; Leiter U; Becker JC; Meissner M; Kleeman J; Pföhler C; Hassel J; Grabbe S; Loquai C
Cancer Immunol Immunother; 2021 Nov; 70(11):3313-3322. PubMed ID: 33870464
[TBL] [Abstract][Full Text] [Related]
20. Avelumab: A Novel Anti-PD-L1 Agent in the Treatment of Merkel Cell Carcinoma and Urothelial Cell Carcinoma.
Teets A; Pham L; Tran EL; Hochmuth L; Deshmukh R
Crit Rev Immunol; 2018; 38(3):159-206. PubMed ID: 30004857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
